Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.

Pfizer0 个研究点开始时间: 2023年9月6日最近更新: 2025年11月18日

适应症

试验速览

阶段: 不适用
状态: Available
发起方: Pfizer

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

Provide pre-approval single patient Expanded Access (Compassionate Use) of Etrasimod for patients.

详细描述

In Expanded Access, treating physicians are the Sponsors. Expanded Access requests from treating physicians may be submitted to www.pfizercares.com. Availability will depend on location and country.

研究设计

研究类型: Expanded Access

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究者

发起方

Pfizer

申办方类型

Industry

责任方

Sponsor

相似试验

No Longer Available

不适用

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)Multiple Myeloma

NCT05238311Pfizer

Available

不适用

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)Metastatic Castration-Resistant Prostate Cancer

NCT05650476Pfizer

Available

不适用

Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)Alopecia Areata

NCT05522556Pfizer

No Longer Available

不适用

Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other TreatmentsCOVID-19

NCT06004128Invivyd, Inc.

Available

不适用

Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)Severe Uncontrolled Atopic Dermatitis

NCT05466578Pfizer